Hypera S.A. Sponsored ADR logo

Hypera S.A. Sponsored ADR (HM6A)

Market Open
11 Aug, 20:00
XSTU XSTU
3. 42
-0.1
-2.8409%
- Market Cap
11.13 P/E Ratio
0.09% Div Yield
0 Volume
0 Eps
3.52
Previous Close
Add Transaction
Day Range
3.42 3.64
Year Range
2.7 4.38
Want to track HM6A and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

HM6A trading today lower at €3.42, a decrease of -2.8409% from yesterday's close, completing a monthly increase of 0% or €0. Over the past 12 months, HM6A stock lost -1.7241%.
HM6A pays dividends to its shareholders, with the most recent payment made on Apr 14, 2026.
The last earnings report, released on Apr 21, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0.2267%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 3 different exchanges and in various currencies, with the primary listing on OTC PINK (USD).

HM6A Chart

Hypera S.A. (HYPMY) Q2 2026 Earnings Call Transcript

Hypera S.A. (HYPMY) Q2 2026 Earnings Call Transcript

Hypera S.A. (HYPMY) Q2 2026 Earnings Call Transcript

Seekingalpha | 14 hours ago
Hypera S.A. (HYPMY) Q4 2024 Earnings Call Transcript

Hypera S.A. (HYPMY) Q4 2024 Earnings Call Transcript

Hypera S.A. (OTCPK:HYPMY) Q4 2023 Earnings Conference Call March 21, 2025 10:00 AM ET Company Participants Breno Toledo Pires de Oliveira - Chief Executive Officer Adalmario Ghovatto Satheler do Couto - Investor Relations Officer Ramon Sanches Frutuoso Silva - Chief Financial Officer Conference Call Participants Joseph Giordano - JP Morgan Robert Ford - Bank of America Mauricio Cepeda - Morgan Stanley Vinicius Figueiredo - Itau BBA Samuel Alves - BTG Pactual Operator Good morning, ladies and gentlemen.

Seekingalpha | 1 year ago
Hypera: Short-Term Pain For Long-Term Gain

Hypera: Short-Term Pain For Long-Term Gain

Hypera is a top pharmaceutical company in Brazil, dominating the OTC market with a strong brand portfolio. Overleveraged acquisitions, Brazil's slowing pharma market, and high interest rates have caused a sharp drop in Hypera's stock over the past five years. The company launched a plan to boost cash flow via reduced receivables and inventory, aiming for long-term profitability but facing short-term earnings challenges.

Seekingalpha | 1 year ago

Hypera S.A. Sponsored ADR (HM6A) FAQ

What is the stock price today?

The current price is €3.42.

On which exchange is it traded?

Hypera S.A. Sponsored ADR is listed on XSTU.

What is its stock symbol?

The ticker symbol is HM6A.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0.09%.

What is its market cap?

As of today, no market cap data is available.

Has Hypera S.A. Sponsored ADR ever had a stock split?

No, there has never been a stock split.

Hypera S.A. Sponsored ADR Profile

Specialty Retail Industry
Consumer Discretionary Sector
Breno Toledo Pires de Oliveira CEO
XSTU Exchange
US44914U1060 ISIN
BR Country
10,564 Employees
6 Jul 2026 Last Dividend
- Last Split
- IPO Date

Overview

Hypera S.A. is a prominent pharmaceutical company based in Brazil, known for its expansive portfolio of healthcare products. Initially established in 2001 under the name Hypermarcas S.A., the company underwent a name change to Hypera S.A. in February 2018, signifying a new era in its history. Operating primarily within Brazil, Hypera S.A. specializes in developing, producing, and marketing a wide range of pharmaceutical products, including prescription medications, over-the-counter (OTC) drugs, and nutritional supplements. Its mission centers on delivering high-quality healthcare solutions to improve the well-being of its consumer base. Headquartered in São Paulo, Brazil, Hypera S.A. stands as a leading entity in the Latin American pharmaceutical landscape.

Products and Services

Hypera S.A. offers an extensive variety of products and services categorized into several segments: pharmaceuticals, consumer health products, and nutritional and vitamin supplements. Listed below are some of the company's notable products and brands:

  • Pharmaceutical Products: The company's strong pharmaceutical portfolio includes prescription medications like Adacne, Addera, Celestamine, and Diprosone among others, catering to various healthcare needs from dermatological solutions to anti-inflammatory agents. They also offer a range of products such as Deciprax, Emprol XR, and Max Sulid, focusing on providing comprehensive healthcare remedies.
  • Sun Protection and Skincare: Under the Mantecorp Skincare brand, Hypera S.A. provides a spectrum of sun protection and moisturizing skin care products, addressing the growing consumer needs for comprehensive dermatological care and protection against harmful UV rays.
  • Consumer Health Products: The company's consumer health sector is symbolized by household names like Apracur, Benegrip, and Neosaldina, catering to everyday health issues such as cold and flu, digestive discomfort, and pain relief. The Neo Química brand is renowned for offering a range of similar and generic drugs, expanding the company’s reach in the consumer health market.
  • Nutritional and Vitamin Supplements: Recognizing the importance of dietary supplements in modern healthcare, Hypera S.A. markets products under the Tamarine, Vitasay, and Zero-Cal brands. These offer solutions for nutritional deficiencies and support overall health and wellness.
  • Generic Medicines: Emphasizing accessibility and affordability, Hypera S.A. provides a wide array of generic medicines including Hydroxyzine, Naproxene, and Omeprazole. This segment ensures patients have access to essential medications at lower costs while maintaining high-quality standards.

Contact Information

Address: Av. Magalhães de Castro, 4800
Phone: 55 11 3627 4206